BRAF V600E inhibition in anaplastic thyroid cancer
MH Rosove, PF Peddi, JA Glaspy - New England Journal of …, 2013 - Mass Medical Soc
MH Rosove, PF Peddi, JA Glaspy
New England Journal of Medicine, 2013•Mass Medical SocBRAF V600E Inhibition in Anaplastic Thyroid Cancer | NEJM Skip to main content NEJM Group
Follow Us Facebook Twitter Instagram YouTube LinkedIn Prepare to become a physician,
build your knowledge, lead a health care organization, and advance your career with NEJM
Group information and services. NEJM Evidence NEW! A digital journal for innovative original
research and fresh, bold ideas in clinical trial design and clinical decision-making. NEJM
Catalyst NEW! Peer-reviewed journal featuring in-depth articles to accelerate the …
Follow Us Facebook Twitter Instagram YouTube LinkedIn Prepare to become a physician,
build your knowledge, lead a health care organization, and advance your career with NEJM
Group information and services. NEJM Evidence NEW! A digital journal for innovative original
research and fresh, bold ideas in clinical trial design and clinical decision-making. NEJM
Catalyst NEW! Peer-reviewed journal featuring in-depth articles to accelerate the …
A patient with rapidly progressive anaplastic thyroid cancer bearing the BRAF V600E mutation has a dramatic response to vemurafenib.
The New England Journal Of Medicine